Incidence of Primary Cancers and Intracranial Tumour Recurrences in Growth Hormone-Treated and Untreated Adult Hypopituitary Patients: Analyses from HypoCCS.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Speculation remains that growth hormone (GH) treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenoma (PA) and craniopharyngioma (CP).

Detaljer

Författare
  • Christopher J Child
  • Daniel Conroy
  • Alan G Zimmermann
  • Whitney Woodmansee
  • Eva Marie Erfurth
  • Leslie Robison
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Endokrinologi och diabetes
Originalspråkengelska
Sidor (från-till)779-790
TidskriftEuropean Journal of Endocrinology
Volym172
Utgivningsnummer6
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa